Why is SANOFI stock price going up?
Bulls say
Commercial performance (Dupixent)
Analyst highlights that Dupixent's strong sales are the primary driver of revenue momentum and provide tangible upside to top-line expectations.
Guidance revision
Raised sales guidance signals stronger demand trends and increases the probability of upside to revenue forecasts.
Strategic repositioning
New CEO's focus on tightening R&D standards and pursuing acquisitions could accelerate pipeline rebuilding and create meaningful value if high-quality deals are executed.
Management clarity
Limited strategic detail from the new CEO on R&D plans and merger intentions leaves execution questions unresolved and could prolong investor uncertainty.
R&D execution risk
Incoming head of R&D's mixed track record implies a likely multi-year turnaround, reducing visibility on future drug progress and potential approvals.
Earnings quality and pipeline
Reported margin improvement relied partly on a one-off accounting reversal and was offset by R&D wind-down charges, raising concerns about earnings quality and underscoring the need for acquisitions to rebuild the pipeline.

